Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRA | P10827 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 3/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.36 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15152717 | 0.85 | THRA (0.51) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL366865 | 0.80 | MAOB (0.56) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL18217412 | 0.76 | MAOB (0.52) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL7738359 | 0.75 | THRA (0.56) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL8104566 | 0.75 | FAAH (0.41) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL31568426 | 0.74 | TSHR (0.62) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL22469788 | 0.74 | TSHR (0.62) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL31469078 | 0.74 | MAOB (0.46) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL31620922 | 0.74 | MAOB (0.50) | THRATHRBMAOBMAOACYP19A1 | |
| SCHEMBL3881721 | 0.74 | THRA (0.47) | THRATHRBMAOBMAOACYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6723753-B2 | TREATING ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES. | PHARMACIA CORPORATION | 2004-04-20 | — | — | US | disclosed |
| US-6699898-B2 | METHOD OF TREATING CORONARY ARTERY DISEASE OR OTHER CETP-MEDIATED DISORDERS IN A SUBJECT BY ADMINISTERING A THERAPEUTICALLY EFFECTIVE AMOUNT OF A COMPOUND OF ONE OF CLAIMS | PHARMACIA CORPORATION GLOBAL PATENT DEPARTMENT | 2004-03-02 | — | — | US | disclosed |
| US-6677375-B2 | TREATING CARDIOVASCULAR DISEASES | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-6677380-B2 | ANTILIPEMIC AGENTS SUCH AS 3(3-(4-CHLORO-3-ETHYL-PHENOXY)-PHENYL)((3-(1,1,2,2 -TETRAFLUOROETHOXY)PHENYL)METHYL))AMINO)-1,1,1-TRIFLURO-2-PROPANTHIOL, USED FOR PROPHLAXIS OF CARDIOVASCULAR DISORDERS AND ATHEROSCLEROSIS | PHARMACIA CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-07-03 | — | — | US | disclosed |
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-07-03 | — | — | US | disclosed |
| US-6586433-B2 | Anticholesterol agents; antilipemic agents; cardiovascular disorders | PHARMACIA CORPORATION | 2003-07-01 | — | — | US | disclosed |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-26 | — | — | US | disclosed |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-06-12 | — | — | US | disclosed |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-06-05 | — | — | US | disclosed |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. (US) | 2003-05-01 | — | — | US | disclosed |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | G.D. SEARLE & CO. | 2003-02-13 | — | — | US | disclosed |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | disclosed |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | SIKORSKI JAMES A (US) | 2002-11-07 | — | — | US | disclosed |
| US-6476057-B1 | ANTICHOLESTEROL AGENTS; ANTILIPEMIC AGENTS; CARDIOVASCULAR DISORDERS | G.D. SEARLE & CO. | 2002-11-05 | — | — | US | disclosed |
| US-6462092-B1 | SUCH AS 3-((3-FLUOROPHENYL)-((3-(TRIFLUOROMETHYL)PHENYL)-METHYL)AMINO)-1,1,1 -TRIFLUORO-2-PROPANOL; CARDIOVASCULAR DISEASE, I.E. ATHEROSCLEROSIS AND OTHER CORONARY ARTERY DISEASES | G.D. SEARLE & CO. | 2002-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030125328-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | THRA 1960/4885THRB 1423/4885MAOB 2046/4885 |
| US-20030105100-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | THRA 1960/4885THRB 1423/4885MAOB 2046/4885 |
| US-20020165231-A1 | Substituted N-heteroaryl-N-phenyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, LCAT, MTTP | THRA 2257/4885THRB 1738/4885MAOB 2495/4885 |
| US-20030109528-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | THRA 1960/4885THRB 1423/4885MAOB 2046/4885 |
| US-20030119833-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | THRA 1960/4885THRB 1423/4885MAOB 2046/4885 |
| US-20030083331-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | THRA 1960/4885THRB 1423/4885MAOB 2046/4885 |
| US-20030032644-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, PCTP | THRA 1082/4885THRB 496/4885MAOB 1050/4885 |
| US-20020165232-A1 | Substituted N, N-disubstituted cycloalkyl aminoalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity | CETP, DBI, PLTP | THRA 2735/4885THRB 1975/4885MAOB 2826/4885 |
| US-20030125329-A1 | Substituted polycyclic aryl and heteroaryl tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity | CETP, MTTP, LCAT | THRA 1960/4885THRB 1423/4885MAOB 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.